Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Oncogenes and Tumor Suppressors

Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations

Mitsuo Sato, Jill E. Larsen, Woochang Lee, Han Sun, David S. Shames, Maithili P. Dalvi, Ruben D. Ramirez, Hao Tang, John Michael DiMaio, Boning Gao, Yang Xie, Ignacio I. Wistuba, Adi F. Gazdar, Jerry W. Shay and John D. Minna
Mitsuo Sato
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jill E. Larsen
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Woochang Lee
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Han Sun
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David S. Shames
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maithili P. Dalvi
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruben D. Ramirez
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hao Tang
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Michael DiMaio
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boning Gao
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Xie
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ignacio I. Wistuba
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adi F. Gazdar
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry W. Shay
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John D. Minna
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
1Hamon Center for Therapeutic Oncology Research; 2Simmons Comprehensive Cancer Center; 3Center for Biostatistics and Clinical Science; Departments of 4Pharmacology, 5Internal Medicine, 6Cardio Thoracic Surgery, 7Pathology, and 8Cell Biology, The University of Texas Southwestern Medical Center, Dallas; 9Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; and 10Center for Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1541-7786.MCR-12-0634-T Published June 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Visual Overview

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Abstract

We used CDK4/hTERT–immortalized normal human bronchial epithelial cells (HBEC) from several individuals to study lung cancer pathogenesis by introducing combinations of common lung cancer oncogenic changes (p53, KRAS, and MYC) and followed the stepwise transformation of HBECs to full malignancy. This model showed that: (i) the combination of five genetic alterations (CDK4, hTERT, sh-p53, KRASV12, and c-MYC) is sufficient for full tumorigenic conversion of HBECs; (ii) genetically identical clones of transformed HBECs exhibit pronounced differences in tumor growth, histology, and differentiation; (iii) HBECs from different individuals vary in their sensitivity to transformation by these oncogenic manipulations; (iv) high levels of KRASV12 are required for full malignant transformation of HBECs, however, prior loss of p53 function is required to prevent oncogene-induced senescence; (v) overexpression of c-MYC greatly enhances malignancy but only in the context of sh-p53+KRASV12; (vi) growth of parental HBECs in serum-containing medium induces differentiation, whereas growth of oncogenically manipulated HBECs in serum increases in vivo tumorigenicity, decreases tumor latency, produces more undifferentiated tumors, and induces epithelial-to-mesenchymal transition (EMT); (vii) oncogenic transformation of HBECs leads to increased sensitivity to standard chemotherapy doublets; (viii) an mRNA signature derived by comparing tumorigenic versus nontumorigenic clones was predictive of outcome in patients with lung cancer. Collectively, our findings show that this HBEC model system can be used to study the effect of oncogenic mutations, their expression levels, and serum-derived environmental effects in malignant transformation, while also providing clinically translatable applications such as development of prognostic signatures and drug response phenotypes.

Visual Overview: http://mcr.aacrjournals.org/content/11/6/638/F1.large.jpg.

Mol Cancer Res; 11(6); 638–50. ©2013 AACR.

This article is featured in Highlights of This Issue, p. 555

Footnotes

  • Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/).

  • Received November 6, 2012.
  • Revision received January 24, 2013.
  • Accepted January 25, 2013.
  • ©2013 American Association for Cancer Research.

View Full Text
PreviousNext
Back to top
Molecular Cancer Research: 11 (6)
June 2013
Volume 11, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations
Mitsuo Sato, Jill E. Larsen, Woochang Lee, Han Sun, David S. Shames, Maithili P. Dalvi, Ruben D. Ramirez, Hao Tang, John Michael DiMaio, Boning Gao, Yang Xie, Ignacio I. Wistuba, Adi F. Gazdar, Jerry W. Shay and John D. Minna
Mol Cancer Res June 1 2013 (11) (6) 638-650; DOI: 10.1158/1541-7786.MCR-12-0634-T

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations
Mitsuo Sato, Jill E. Larsen, Woochang Lee, Han Sun, David S. Shames, Maithili P. Dalvi, Ruben D. Ramirez, Hao Tang, John Michael DiMaio, Boning Gao, Yang Xie, Ignacio I. Wistuba, Adi F. Gazdar, Jerry W. Shay and John D. Minna
Mol Cancer Res June 1 2013 (11) (6) 638-650; DOI: 10.1158/1541-7786.MCR-12-0634-T
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Visual Overview
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Mechanisms of V561M FGFR1–Driven Drug Resistance
  • DDX3X in DNA Damage and Liver Tumorigenesis
  • Achilles’ Heel of Brain-Metastatic Breast Cancer
Show more Oncogenes and Tumor Suppressors
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement